Clinical efficacy analysis of Shibao Decoction in the treatment of late-onset hypogonadism with kidney essence deficiency.
- Author:
Shao-Kang CHEN
1
;
Yi SHAN
1
;
Zhen-Fu SHI
2
;
Hai-Feng XU
2
;
Yao-Hua ZHANG
2
;
Yi LU
2
Author Information
1. College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia 750004, China.
2. Department of Surgery, Yinchuan Hospital of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia 750001, China.
- Publication Type:English Abstract
- Keywords:
late-onset hypogonadism;
Shibao decoction;
testosterone;
skeletal muscle mass;
insulin resistance
- MeSH:
Humans;
Hypogonadism/etiology*;
Drugs, Chinese Herbal/therapeutic use*;
Male;
Testosterone/therapeutic use*;
Treatment Outcome;
Sex Hormone-Binding Globulin;
Medicine, Chinese Traditional;
Middle Aged;
Adult;
Kidney
- From:
National Journal of Andrology
2025;31(7):630-636
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinical efficacy of "Shibao Decoction" in the management of late-onset hypogonadism (LOH) caused by deficiency of kidney essence.
METHODS:Sixty male patients with late-onset hypogonadism of kidney essence deficiency type were randomly assigned to the treatment group and the control group, each with 30 cases. The patients in treatment group were treated with oral Shibao Decoction, while the control group was treated with oral Testosterone Undecanoate Capsules. The patients in both groups were treated for 12 weeks. The PADAM symptom score, TCM syndrome score, serum total testosterone (TT), serum free testosterone (FT), sex hormone binding globulin (SHBG), body mass index (BMI), total skeletal muscle mass index (SMI), appendicular skeletal muscle mass index (ASMI), FBG, FINS, and insulin resistance index (HOMA-IR) levels were compared between the two groups.
RESULTS:After treatment, PADAM scores for each item and TCM symptoms score decreased, TT and FT increased in both groups, all with statistically significant differences from those of pre-treatment (P<0.05). The level of SHBG in the control group decreased (P<0.05), which had not changed significantly in the treatment group (P>0.05). After treatment, SMI and ASMI increased in both groups significantly (P<0.05). BMI decreased in the control group (P<0.05), which had not changed significantly in the treatment group (P>0.05). The level of FINS decreased in the control group (P<0.05), which had not changed significantly in the treatment group (P>0.05). FPG had not changed significantly in both groups (P>0.05), and the insulin resistance index (HOMA-IR) had significantly improved in both groups, all with statistically significant differences from those of pre-treatment (P<0.05). After treatment, the total effective rates of PADAM score and TCM syndrome score in the treatment group were 73.3% and 86.6% respectively, and the total effective rates in the control group were 66.7% and 76.6% respectively. The total effective rates of the two scores in the treatment group were slightly higher than those in the control group (P>0.05). There was no significant difference in the indicators between the two groups after treatment, and the treatment group is generally comparable with the control group in the therapeutic effects (P>0.05). And no adverse reactions occurred during treatment in both groups.
CONCLUSION:The "Shibao Decoction" has a remarkable therapeutic effect on late-onset hypogonadism caused by deficiency of kidney essence and has good safety. It can be used as an alternative to testosterone undecanoate and is worthy of clinical promotion and application.
